Boosted Danoprevir Improves Response in Prior Null Responders

[Guest guest]

Boosted Danoprevir Improves Response in Prior Null Responders

SUMMARY

Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with

ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced

early virological response at week 12, but breakthrough reached 50% for those

with genotype 1a.

[Guest guest]

Boosted Danoprevir Improves Response in Prior Null Responders

SUMMARY

Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with

ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced

early virological response at week 12, but breakthrough reached 50% for those

with genotype 1a.

[Guest guest]

Boosted Danoprevir Improves Response in Prior Null Responders

SUMMARY

Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with

ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced

early virological response at week 12, but breakthrough reached 50% for those

with genotype 1a.

[Guest guest]

Boosted Danoprevir Improves Response in Prior Null Responders

SUMMARY

Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with

ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced

early virological response at week 12, but breakthrough reached 50% for those

with genotype 1a.